Print

Biogen Idec Canada Release: Health Canada Approves TECFIDERA™ as a First-Line Oral Treatment for Multiple Sclerosis  
4/9/2013 10:36:41 AM

MISSISSAUGA, ON, April 9, 2013 /CNW/ - Today, Biogen Idec Canada announced the Health Canada approval of TECFIDERAâ„¢ (dimethyl fumarate) delayed-release capsules, formerly BG-12, as a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERA is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.1
//-->